These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34137699)

  • 61. Convalescent plasma for SARS-CoV-2 infection: win or learn.
    Contreras-Barbeta E; Millan A; Rello J
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34531275
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
    Joob B; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
    [No Abstract]   [Full Text] [Related]  

  • 64. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
    Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
    Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
    Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
    Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
    Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
    Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
    [No Abstract]   [Full Text] [Related]  

  • 68. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
    Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
    J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
    Gharbharan A; GeurtsvanKessel CH; Jordans CCE; Blaauw M; van der Klift M; Hassing RJ; Smits-Zwinkels M; Meertens M; van den Hout EC; de Man AM; Hageman I; Bogers S; van der Schoot CE; Swaneveld F; Anas AA; Rokx C; Rijnders BJA
    Clin Infect Dis; 2022 Apr; 74(7):1271-1274. PubMed ID: 34293119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia.
    González SE; Regairaz L; Salazar MR; Ferrando NS; González Martínez VV; Carrera Ramos PM; Pesci SA; Vidal JM; Kreplak N; Estenssoro E
    J Investig Med; 2022 Jun; 70(5):1258-1264. PubMed ID: 35135872
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
    Destremau M; Chaussade H; Hemar V; Beguet M; Bellecave P; Blanchard E; Barret A; Laboure G; Vasco-Moynet C; Lacassin F; Morisse E; Aguilar C; Lafarge X; Lafon ME; Bonnet F; Issa N; Camou F
    J Med Virol; 2024 Apr; 96(4):e29603. PubMed ID: 38619025
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
    Zerbit J; Detroit M; Meyer A; Decroocq J; Deau-Fischer B; Deschamps P; Birsen R; Mondesir J; Franchi P; Miekoutima E; Guerin C; Batista R; Bouscary D; Willems L; Vignon M
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366475
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hematological aspects of the COVID-19 syndrome.
    Malkan UY; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(12):4463-4476. PubMed ID: 35776048
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Coronavirus Disease-2019 in the Immunocompromised Host.
    Bertini CD; Khawaja F; Sheshadri A
    Clin Chest Med; 2023 Jun; 44(2):395-406. PubMed ID: 37085228
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Features of COVID-19 infection among patients with hematological malignancies].
    Fissore G; Skog S; Lastra J; Chandía M
    Rev Med Chil; 2022 May; 150(5):625-633. PubMed ID: 37906763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Coronavirus Disease-2019 in the Immunocompromised Host.
    Bertini CD; Khawaja F; Sheshadri A
    Infect Dis Clin North Am; 2024 Mar; 38(1):213-228. PubMed ID: 38280765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. COVID-19 in hematological malignancies: Case series and literature review.
    Ocheni S; Nwagha TU; Amu N; Obodo OI; Okereke K; Chikezie K; Ejezie CS; Ilechukwu GU; Obiatuegwu C
    Ann Afr Med; 2023; 22(3):381-384. PubMed ID: 37417029
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants.
    Abbasi J
    JAMA; 2021 May; 325(20):2033-2035. PubMed ID: 33950236
    [No Abstract]   [Full Text] [Related]  

  • 80. Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.
    Seval GC; Topçuoğlu P; Demirer T
    Turk J Med Sci; 2021 Dec; 51(6):2799-2809. PubMed ID: 33705648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.